Diabetic Nephropathy - Pipeline Review, H1 2017
ReportsWeb.com has announced the addition of the “Diabetic Nephropathy - Pipeline Review, H1 2017” this report provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.
(EMAILWIRE.COM, July 07, 2017 ) Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 15, 6, 30, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/diabetic-nephropathy-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders) .
- The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001709497/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
AbbVie Inc
Allergan Plc
Antisense Therapeutics Ltd
Aptevo Therapeutics Inc
Araim Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BLR Bio LLC
Boehringer Ingelheim GmbH
Cellmid Ltd
ChemoCentryx Inc
CSL Ltd
Daiichi Sankyo Company Ltd
DiaMedica Therapeutics Inc
Dynamis Therapeutics Inc
Galectin Therapeutics Inc
GenKyoTex SA
Gilead Sciences Inc
GNI Group Ltd
Islet Sciences Inc
Jenrin Discovery Inc
Johnson & Johnson
Mallinckrodt Plc
Mesoblast Ltd
Mitsubishi Tanabe Pharma Corp
MorphoSys AG
Novartis AG
Noxxon Pharma AG
Omeros Corp
PhiloGene Inc
PhytoHealth Corp
ProMetic Life Sciences Inc
RegenMedTX LLC
Serodus ASA
Teijin Pharma Ltd
Theravance Biopharma Inc
Variant Pharmaceuticals Inc
Vascular Pharmaceuticals Inc
Vicore Pharma AB
XORTX Pharma Corp
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001709497/discount
List of Tables
Number of Products under Development for Diabetic Nephropathy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Diabetic Nephropathy - Pipeline by AbbVie Inc, H1 2017
Diabetic Nephropathy - Pipeline by Allergan Plc, H1 2017
Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Aptevo Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, H1 2017
Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H1 2017
Diabetic Nephropathy - Pipeline by Bayer AG, H1 2017
Diabetic Nephropathy - Pipeline by BLR Bio LLC, H1 2017
Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Diabetic Nephropathy - Pipeline by Cellmid Ltd, H1 2017
Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, H1 2017
Diabetic Nephropathy - Pipeline by CSL Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Diabetic Nephropathy - Pipeline by DiaMedica Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by Dynamis Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by Galectin Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by GenKyoTex SA, H1 2017
Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, H1 2017
Diabetic Nephropathy - Pipeline by GNI Group Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Islet Sciences Inc, H1 2017
Diabetic Nephropathy - Pipeline by Jenrin Discovery Inc, H1 2017
Diabetic Nephropathy - Pipeline by Johnson & Johnson, H1 2017
Diabetic Nephropathy - Pipeline by Mallinckrodt Plc, H1 2017
Diabetic Nephropathy - Pipeline by Mesoblast Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
Diabetic Nephropathy - Pipeline by MorphoSys AG, H1 2017
Diabetic Nephropathy - Pipeline by Novartis AG, H1 2017
Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H1 2017
Diabetic Nephropathy - Pipeline by Omeros Corp, H1 2017
Diabetic Nephropathy - Pipeline by PhiloGene Inc, H1 2017
Diabetic Nephropathy - Pipeline by PhytoHealth Corp, H1 2017
Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc, H1 2017
Diabetic Nephropathy - Pipeline by RegenMedTX LLC, H1 2017
Diabetic Nephropathy - Pipeline by Serodus ASA, H1 2017
Diabetic Nephropathy - Pipeline by Teijin Pharma Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Theravance Biopharma Inc, H1 2017
Diabetic Nephropathy - Pipeline by Variant Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H1 2017
Diabetic Nephropathy - Pipeline by XORTX Pharma Corp, H1 2017
Diabetic Nephropathy - Dormant Projects, H1 2017
Diabetic Nephropathy - Dormant Projects, H1 2017 (Contd..1) , H1 2017
Diabetic Nephropathy - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001709497/buy/2000
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 15, 6, 30, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.
Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/diabetic-nephropathy-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders) .
- The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001709497/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
AbbVie Inc
Allergan Plc
Antisense Therapeutics Ltd
Aptevo Therapeutics Inc
Araim Pharmaceuticals Inc
Arena Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BLR Bio LLC
Boehringer Ingelheim GmbH
Cellmid Ltd
ChemoCentryx Inc
CSL Ltd
Daiichi Sankyo Company Ltd
DiaMedica Therapeutics Inc
Dynamis Therapeutics Inc
Galectin Therapeutics Inc
GenKyoTex SA
Gilead Sciences Inc
GNI Group Ltd
Islet Sciences Inc
Jenrin Discovery Inc
Johnson & Johnson
Mallinckrodt Plc
Mesoblast Ltd
Mitsubishi Tanabe Pharma Corp
MorphoSys AG
Novartis AG
Noxxon Pharma AG
Omeros Corp
PhiloGene Inc
PhytoHealth Corp
ProMetic Life Sciences Inc
RegenMedTX LLC
Serodus ASA
Teijin Pharma Ltd
Theravance Biopharma Inc
Variant Pharmaceuticals Inc
Vascular Pharmaceuticals Inc
Vicore Pharma AB
XORTX Pharma Corp
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001709497/discount
List of Tables
Number of Products under Development for Diabetic Nephropathy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Diabetic Nephropathy - Pipeline by AbbVie Inc, H1 2017
Diabetic Nephropathy - Pipeline by Allergan Plc, H1 2017
Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Aptevo Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Arena Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, H1 2017
Diabetic Nephropathy - Pipeline by AstraZeneca Plc, H1 2017
Diabetic Nephropathy - Pipeline by Bayer AG, H1 2017
Diabetic Nephropathy - Pipeline by BLR Bio LLC, H1 2017
Diabetic Nephropathy - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Diabetic Nephropathy - Pipeline by Cellmid Ltd, H1 2017
Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, H1 2017
Diabetic Nephropathy - Pipeline by CSL Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
Diabetic Nephropathy - Pipeline by DiaMedica Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by Dynamis Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by Galectin Therapeutics Inc, H1 2017
Diabetic Nephropathy - Pipeline by GenKyoTex SA, H1 2017
Diabetic Nephropathy - Pipeline by Gilead Sciences Inc, H1 2017
Diabetic Nephropathy - Pipeline by GNI Group Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Islet Sciences Inc, H1 2017
Diabetic Nephropathy - Pipeline by Jenrin Discovery Inc, H1 2017
Diabetic Nephropathy - Pipeline by Johnson & Johnson, H1 2017
Diabetic Nephropathy - Pipeline by Mallinckrodt Plc, H1 2017
Diabetic Nephropathy - Pipeline by Mesoblast Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017
Diabetic Nephropathy - Pipeline by MorphoSys AG, H1 2017
Diabetic Nephropathy - Pipeline by Novartis AG, H1 2017
Diabetic Nephropathy - Pipeline by Noxxon Pharma AG, H1 2017
Diabetic Nephropathy - Pipeline by Omeros Corp, H1 2017
Diabetic Nephropathy - Pipeline by PhiloGene Inc, H1 2017
Diabetic Nephropathy - Pipeline by PhytoHealth Corp, H1 2017
Diabetic Nephropathy - Pipeline by ProMetic Life Sciences Inc, H1 2017
Diabetic Nephropathy - Pipeline by RegenMedTX LLC, H1 2017
Diabetic Nephropathy - Pipeline by Serodus ASA, H1 2017
Diabetic Nephropathy - Pipeline by Teijin Pharma Ltd, H1 2017
Diabetic Nephropathy - Pipeline by Theravance Biopharma Inc, H1 2017
Diabetic Nephropathy - Pipeline by Variant Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Vascular Pharmaceuticals Inc, H1 2017
Diabetic Nephropathy - Pipeline by Vicore Pharma AB, H1 2017
Diabetic Nephropathy - Pipeline by XORTX Pharma Corp, H1 2017
Diabetic Nephropathy - Dormant Projects, H1 2017
Diabetic Nephropathy - Dormant Projects, H1 2017 (Contd..1) , H1 2017
Diabetic Nephropathy - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001709497/buy/2000
Contact Information:
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Priya Sisodia
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results